Sagimet Biosciences

Clinical-stage biotech developing oral selective fatty acid synthase (FASN) inhibitors for metabolic-driven diseases. Lead asset denifanstat hit Phase 3 in moderate-to-severe acne in China (NDA accepted by NMPA Dec 2025) and showed positive Phase 2b data in MASH; a U.S. Phase 3 acne trial is planned for 2H 2026 and a $175M offering closed in early 2026.